| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8417115 | Journal of Immunological Methods | 2016 | 33 Pages |
Abstract
The TCC capacity may represent a novel and easy to perform parameter to determine level of complement inhibition in patients treated with eculizumab, especially because it identifies the residual capacity of inhibition at pathophysiological stages.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Magdalena Riedl, Johannes Hofer, Thomas Giner, Alejandra Rosales, Karsten Häffner, Giacomo D. Simonetti, Ulrike Walden, Tanja Maier, Dorothea Heininger, Verena Jeller, Günter Weiss, Lambert van den Heuvel, Lothar B. Zimmerhackl, Reinhard Würzner,